Alentis Therapeutics, a leading biopharmaceutical company developing targeted treatments for cancer and fibrotic diseases, has secured $181.4 million in Series D funding round to develop targeted therapies for solid tumors. The financing round was spearheaded by OrbiMed, Novo Holdings and Jeito Capital, with significant contributions from new investors Longitude Capital, Frazier Life Sciences, Catalio Capital, Avego Bioscience Capital, and Piper Heartland Healthcare Capital.